Pyrazolam Stats & Data
Brc1ccc2c(c1)C(=NCc1nnc(C)n12)c1ccccn1BGRWSFIQQPVEML-UHFFFAOYSA-NInteraction Warnings
This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
It is dangerous to combine benzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified disinhibition as well as other effects.
Receptor Profile
Receptor Actions
History & Culture
Pyrazolam was originally developed during the 1970s by a research team led by Leo Sternbach at Hoffman-La Roche, the pharmaceutical company responsible for discovering many clinically significant benzodiazepines. Despite its initial synthesis during this prolific period of benzodiazepine research, pyrazolam was never pursued for clinical development or pharmaceutical marketing. The compound remained obscure for several decades until it was "rediscovered" and began appearing on the online research chemical market around 2012. The first official analytical report identifying pyrazolam as a novel substance originated from Finland in 2011, with subsequent reports emerging from the United Kingdom in 2012. Since its emergence, pyrazolam has become established as one of several designer benzodiazepines circulating within the research chemical community, valued particularly for its reported anxiolytic selectivity relative to other effects typical of the benzodiazepine class.
Subjective Effect Notes
physical: The physical effects of pyrazolam can be broken down into several components which progressively intensify proportional to dosage.
cognitive: The general head space of pyrazolam is described by many as one of mild sedation and proportionlly intense anxiety suppression. It contains a large number of typical depressant cognitive effects.
Effect Profile
Curated + 9 ReportsStrong anxiolysis and cognitive impairment with moderate euphoria, mild sedation
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
As with other benzodiazepines, tolerance to sedative/hypnotic effects can build within days of repeated dosing; anxiolytic tolerance may develop more gradually. Rough recovery to baseline often requires several weeks off. Estimates here are conservative and based on general benzo patterns and user reports, not controlled studies.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 9 experience reports (9 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 5
Adverse Effects 2
Real-World Dose Distribution
62K DosesFrom 215 individual dose entries
Oral (n=204)
Form / Preparation
Most common forms and preparations reported
Benzodiazepine Equivalence
Pyrazolam - 1-2mg ~=10mg Diazepam.
Legal Status
| Country | Status | Notes |
|---|---|---|
| Canada | Schedule IV (CDSA) | Controlled under the Controlled Drugs and Substances Act as part of the blanket scheduling of all benzodiazepines. Possession, trafficking, and production without authorization carry criminal penalties. |
| Germany | NpSG controlled | Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty. |
| Russia | Schedule III | Listed as a Schedule III controlled substance since 2017. Production, distribution, and possession are regulated under federal drug control legislation. |
| Sweden | Controlled substance | Classified as a controlled narcotic substance under Swedish drug legislation. Possession, sale, and distribution are prohibited. |
| Switzerland | Verzeichnis E | Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession and distribution are prohibited. |
| Turkey | Illegal | Classified as an illegal drug under Turkish drug control laws. Possession, production, supply, and importation are all criminal offenses. |
| United Kingdom | Class C | Controlled as a Class C substance under the Misuse of Drugs Act 1971 since May 31, 2017. Prior to this, a Temporary Class Drug Order (TCDO) issued in December 2016 had already prohibited personal possession, not just import and supply. It is illegal to possess, produce, or supply. |
Harm Reduction
drugs.wiki• Potency is in the low milligram range, increasing the risk of accidental over- or redosing if pellets/liquids are mislabelled or non-uniform; multiple user reports since 2024–2025 describe “pyrazolam” products that appeared to be norflurazepam or otherwise inconsistent—use drug checking where possible and treat new batches as unknown potency. • The come-up can be slower and more gradual than many expect; some users don’t feel full effects until ~2–3 hours. Avoid redosing early; wait at least 2–3 hours before considering more to reduce blackout risk. • Like other benzodiazepines, pyrazolam can cause anterograde amnesia, impaired coordination, and “functionality illusions” (feeling calm while motor skills and judgment are impaired). Do not drive or perform safety-critical tasks. • Combining with other depressants (alcohol, opioids, GHB/GBL, barbiturates, Z‑drugs) greatly increases overdose risk via additive respiratory depression; harm-reduction groups flag benzo–opioid combos as a key driver of poisonings. • Dependence and difficult withdrawal (including seizures) are documented across the new/illicit benzodiazepines category; avoid frequent use and do not stop abruptly after extended use—seek medical guidance for tapering. • Given the variability and mislabeling in this market, volumetric dosing (dissolving a known quantity into a measured volume and dosing by volume) can reduce dose error; TripSit provides a calculator and guidance. • Some community reports claim pyrazolam dissolves readily in water; others note pH-dependent solubility similar to midazolam. Treat solubility claims cautiously; if making solutions, use appropriate solvents/containers and label clearly to prevent accidental ingestion. • Designer/illicit benzodiazepines are sometimes found in opioid samples (“benzo-dope”); if using opioids, assume possible benzo co-exposure and carry naloxone—but note naloxone does not reverse benzodiazepines. • Legal status varies and can change quickly. In the UK and many EU countries, new benzodiazepines including pyrazolam have been targeted by controls; possession/supply may be illegal. • Amnestic effects increase steeply with dose and with combinations; users report blackouts at higher doses or with stacked redoses—consider a trusted sober sitter if experimenting.
References
Data Sources
Cited References
- Drug Users Bible: Pyrazolam
- Moosmann et al. 2013: Characterization of the designer benzodiazepine pyrazolam
- PMC: New/Designer Benzodiazepines Analysis
- PMC: Recent findings on designer benzodiazepines
- TripSit: Risks of Combining Depressants
- TripSit Factsheet: Pyrazolam
- DrugBank: Pyrazolam Interactions
Drugs.wiki References
- DrugBank: Pyrazolam (identifiers, synonyms)
- TripSit Wiki: Benzodiazepines (equivalence/short-acting class listing)
- TripSit: Drug combinations (benzos with other depressants flagged dangerous)
- TripSit: Resources incl. volumetric converter
- Erowid: Novel Drug Briefs (Pyrazolam profile; drawn-out come-up, amnesia/blackout traits)
- Erowid References DB: Abouchedid et al., 2018 (availability/misuse motivations of pyrazolam etc.)
- EUDA/EMCDDA: New benzodiazepines in Europe – a review (public health risks)
- EUDA/EMCDDA news: Designer benzodiazepines risks & availability
- Drug checking data context: ‘benzo-dope’ observations (Toronto’s Drug Checking Service)